The pretargeting technique referred to as the Affinity Enhancement System (AES) uses bispecific antibodies and radiolabeled bivalent haptens that bind cooperatively to target cells in vivo. Experimental and clinical data demonstrate that AES can deliver large radiation doses to tumor cells with high tumor to normal tissue contrast ratios and long activity residence time in tumors. Preliminary clinical results of radioimmunotherapy of medullary thyroid carcinomas and lung cancers look promising.
No takes yet. Share an insight, caveat, or question.
Barbet et al. (1999) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: